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Dendritic cells in acute 
kidney injury
During ischemia, the production of 
cytokines by resident cells as well as 
bone marrow-derived cells produces an 
infl ammatory response that is clearly 
pathogenic. Among these cytokines, 
tumor necrosis factor (TNF)-α is 
especially culpable. As they report in 
this issue, Dong et al. isolated cells to 
determine the contribution of dendritic 
cells to the early production of TNF and 
other infl ammatory mediators. Th ey 
increased secretion of TNF, interleukin-
6, monocyte chemoattractant protein-1, 
and RANTES in cell suspensions taken 
from ischemic kidneys as compared with 
control kidneys. When these suspensions 
were enriched for dendritic cells, the 
cytokine production further increased, 
and specifi cally identifi ed TNF-α. When 
bone marrow-derived dendritic cells were 
isolated aft er ischemia to the kidney, they 
exhibited maturation markers, although 
their numbers were stable. Dendritic cells 
were the predominant cells to produce 
TNF-α. When depleted from the kidneys 
in vivo, dendritic cells substantially 
attenuated TNF secretion by renal cells 
in response to ischemic injury. Previous 
identifi cation of resident dendritic cells 
in the kidney was a major discovery 
in kidney research; Dong et al. further 
expand the domain of these important 
cells in renal disease. See page 619.
Long-term survival of 
acute renal failure
What is the long-term outcome of 
patients with acute tubular necrosis 
(ATN)? Th ere is a dearth of studies that 
address this question. In a new article, 
Liaño et al. studied patients with ATN at 
a single hospital in Madrid and followed 
those who were discharged for an 
average of 7 years. As would be expected, 
many died — a large number of them 
because of diseases present when they 
developed ATN. Detailed analysis did 
not show many surprises. Th ose who 
survived were younger and had survived 
trauma; hence, they developed ATN 
without any comorbid events. Many of 
those who survived had been treated in 
the intensive care unit of the hospital. 
Although the long-term mortality in this 
group of patients was high and related to 
the original disease, renal function was 
found to be adequate in most patients. 
See page 679.
Anti-dsDNA antibodies 
in lupus nephritis bind 
to nucleosomes
One of the hallmarks of lupus nephritis 
is the association of the disease and 
its severity with anti-double-stranded 
DNA (anti-dsDNA) antibodies. 
Antigen–antibody complexes made 
with these antibodies have been found 
to be nephritogenic. However, before 
now, the target of these antibodies 
was unknown. Th e major problem in 
identifying the target is that DNA is a 
highly negatively charged compound; 
hence, the antibodies probably bind by 
electrostatic interactions. Th is causes 
a serious issue in identifi cation of 
the antigen, as any highly negatively 
charged protein could bind to these 
antibodies. Previous studies showed 
that DNase treatment of glomerular 
extracts of lupus kidneys did not reduce 
binding of the antibodies, even though 
addition of dsDNA did reduce binding. 
Th ese previous studies show that 
there may be a crossreacting antigen 
that resembles DNA, such as heparan 
sulfate proteoglycan. Located in the 
glomerular basement membrane, it is 
highly negatively charged. New research 
by Kalaaji et al. re-examined this issue. 
Th ey found that the antibodies were 
restricted to dense deposits in the 
basement membrane and colocalized 
with nucleosome-binding anti-dsDNA/
anti-histone/anti-transcription factor 
antibodies. Th e authors excluded the 
possibility that the dense deposits 
contained dsDNA. Th e targeting of 
membrane-associated nucleosomes 
by anti-dsDNA autoantibodies in 
human lupus nephritis suggests 
that nucleosomes are released in the 
glomerulus — probably from apoptotic 
cells — and act as antigens. See page 664. 
An accompanying Commentary by 
Berden and colleagues puts this work in 
its historical context (see page 600). 
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